Endpoints News

Pfizer's new obesity discovery head		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Th Fri

10 July, 2026

news

The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy

Peer Review

Pfizer appoints obesity discovery head; AI startup Xaira makes leadership adjustments

Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset

ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?

Jul 30

1:00 pm ET

Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights

sponsored by IBM

The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.

ENDPOINTS PHARMA

HHS advances plan to pay out Covid-19 vaccine injury claims

FDA quietly stops releasing CRLs

UK price watchdog recommends against Amgen's Lumakras in lung cancer

FDA criticizes Lundbeck for now-deleted webpages promoting its migraine treatment

in case you missed it

Lilly was already pharma's biggest company. Now it's doing deals to match

Updated: AstraZeneca sinks on unexpected heart drug trial failure

GSK walks away from Alector pact as immuno-neurology bet fizzles

News Briefing

Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfront

Why we don’t know what food is spreading the parasite sickening thousands

UK minister defends US pharma deal following calls to scrap it

After Novo Nordisk exited cell therapy in October, the California biotech Cellular Intelligence pounced on one of the defunct technologies. The company spoke to Lei Lei Wu about early data on a Parkinson's disease stem cell therapy. Get the details here.

Elizabeth Cairns

Senior Biopharma Journalist, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com